168 related articles for article (PubMed ID: 36760735)
1. Exploring structural effects in a new class of NRF2 inhibitors.
Hou Z; Lockwood L; Zhang D; Occhiuto CJ; Mo L; Aldrich KE; Stoub HE; Gallo KA; Liby KT; Odom AL
RSC Med Chem; 2023 Jan; 14(1):74-84. PubMed ID: 36760735
[TBL] [Abstract][Full Text] [Related]
2. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
To C; Ringelberg CS; Royce DB; Williams CR; Risingsong R; Sporn MB; Liby KT
Carcinogenesis; 2015 Jul; 36(7):769-81. PubMed ID: 25939751
[TBL] [Abstract][Full Text] [Related]
5. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
6. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p62-Keap1-Nrf2 Pathway Activation by Realgar Promotes the Inhibition of Esophageal Cancer Cell Proliferation, Migration, and Ferroptosis.
Zhang X; Yang R; Wang H; Cao C; Zhao W; Duan L; Chen F
Curr Drug Deliv; 2024; 21(2):236-248. PubMed ID: 36573061
[TBL] [Abstract][Full Text] [Related]
8. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.
Zhang P; Singh A; Yegnasubramanian S; Esopi D; Kombairaju P; Bodas M; Wu H; Bova SG; Biswal S
Mol Cancer Ther; 2010 Feb; 9(2):336-46. PubMed ID: 20124447
[TBL] [Abstract][Full Text] [Related]
9. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
11. Alkaloids as Natural NRF2 Inhibitors: Chemoprevention and Cytotoxic Action in Cancer.
Gjorgieva Ackova D; Maksimova V; Smilkov K; Buttari B; Arese M; Saso L
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375797
[TBL] [Abstract][Full Text] [Related]
12. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells.
Yang X; Wang D; Ma Y; Xu X; Zhu Z; Wang X; Deng H; Li C; Chen M; Tong J; Yamanaka K; An Y
Toxicol Appl Pharmacol; 2015 Dec; 289(2):231-9. PubMed ID: 26420645
[TBL] [Abstract][Full Text] [Related]
13. A Complementary Chemical and Genomic Screening Approach for Druggable Targets in the Nrf2 Pathway and Small Molecule Inhibitors to Overcome Cancer Cell Drug Resistance.
Matthews JH; Liang X; Paul VJ; Luesch H
ACS Chem Biol; 2018 May; 13(5):1189-1199. PubMed ID: 29565554
[TBL] [Abstract][Full Text] [Related]
14. Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia.
Toth RK; Warfel NA
Antioxidants (Basel); 2017 Apr; 6(2):. PubMed ID: 28383481
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic functions of the transcription factor Nrf2.
Gañán-Gómez I; Wei Y; Yang H; Boyano-Adánez MC; García-Manero G
Free Radic Biol Med; 2013 Dec; 65():750-764. PubMed ID: 23820265
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Stable, Non-Canonically Regulated Nrf2 Form in Lung Cancer Cells.
Mikac S; Rychłowski M; Dziadosz A; Szabelska-Beresewicz A; Fahraeus R; Hupp T; Sznarkowska A
Antioxidants (Basel); 2021 May; 10(5):. PubMed ID: 34063559
[TBL] [Abstract][Full Text] [Related]
17. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.
Tang X; Wang H; Fan L; Wu X; Xin A; Ren H; Wang XJ
Free Radic Biol Med; 2011 Jun; 50(11):1599-609. PubMed ID: 21402146
[TBL] [Abstract][Full Text] [Related]
18. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
19. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
20. Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment.
Zhang J; Xu HX; Zhu JQ; Dou YX; Xian YF; Lin ZX
Int J Biol Sci; 2023; 19(10):3029-3041. PubMed ID: 37416770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
